Search Results

How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

• Authors : Smetana GW; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (G.W.S., R.B.B.).; Romeo GR

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

• Source: Annals of internal medicine [Ann Intern Med] 2024 Jun; Vol. 177 (6), pp. 800-811. Date of Electronic Publication: 2024 Jun 11.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Type 2 Diabetes.

• Authors : Crawford AL; The University of Chicago Medical Center, Chicago, Illinois (A.L.C.).; Laiteerapong N

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/therapeutic use

• Source: Annals of internal medicine [Ann Intern Med] 2024 Jun; Vol. 177 (6), pp. ITC81-ITC96. Date of Electronic Publication: 2024 Jun 11.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.

• Authors : Yen FS; Dr. Yen's Clinic, Taoyuan, Taiwan (F.-S.Y.).; Hwu CM

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

• Source: Annals of internal medicine [Ann Intern Med] 2024 Jun; Vol. 177 (6), pp. 693-700. Date of Electronic Publication: 2024 Apr 30.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.

• Authors : Bates ER; University of Michigan, Ann Arbor, Michigan, USA (E.R.B.).

Subjects: Colchicine*/Colchicine*/Colchicine*/therapeutic use ; Colchicine*/Colchicine*/Colchicine*/administration & dosage ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. JC54. Date of Electronic Publication: 2024 May 07.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.

• Authors : Syed FZ; Duke University Division of General Internal Medicine, Durham, North Carolina.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/economics ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/economics

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. 680-681. Date of Electronic Publication: 2024 Apr 19.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.

• Authors : Schousboe JT; Park Nicollet Clinic and HealthPartners Institute, Bloomington, and Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota (J.T.S.).; Landsteiner A

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/economics ; Cost-Benefit Analysis*

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. 633-642. Date of Electronic Publication: 2024 Apr 19.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.

• Authors : O'Brien C; Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland (C.O., S.F.D.).; Dinneen SF

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. JC55. Date of Electronic Publication: 2024 May 07.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.

• Authors : Hwang JH; Chung-Ang University College of Medicine, Seoul, South Korea, and University of California, San Francisco, California, USA (J.H.H.).; Hsu CY

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/complications

• Source: Annals of internal medicine [Ann Intern Med] 2024 Apr; Vol. 177 (4), pp. JC40. Date of Electronic Publication: 2024 Apr 02.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.

• Authors : Drake T; Department of Medicine, VA Health Care System, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota (T.D., C.J.B., A.K.).; Landsteiner A

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/adverse effects

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. 618-632. Date of Electronic Publication: 2024 Apr 19.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details

Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/therapeutic use; Humans

• Source: Annals of internal medicine [Ann Intern Med] 2024 May; Vol. 177 (5), pp. eM240803. Date of Electronic Publication: 2024 Apr 19.Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model:

Record details